Publication search

UMI or not UMI, that is the question for scRNA-seq zero-inflation

Published in Nature Biotechnology

Hunt for improved monoclonals against coronavirus gathers pace

Published in Nature Biotechnology

Following mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes.

BTK blockers make headway in multiple sclerosis

Published in Nature Biotechnology

By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.

First small-molecule drug targeting RNA gains momentum

Published in Nature Biotechnology

The new drug not only is a boon for patients with spinal muscular atrophy, but also may spearhead the development of further chemical RNA modulators for a broad range of conditions.

Immersive virtual reality as a competitive training strategy for the biopharma industry

Published in Nature Biotechnology

Immersive virtual reality simulations tailored to aspiring industry operators in biopharma manufacturing could become a cost-effective alternative to real-life training for teaching practical skills.

An administrative fix for manufacturing process patent thickets

Published in Nature Biotechnology

Biosimilar manufacturing process patent applications first filed more than a year after the biologic is approved, which represent the largest source of patent assertions in biosimilar litigation, could be addressed without requiring intervention by either the courts or Congress.

EEG-based model and antidepressant response

Published in Nature Biotechnology

Ananda Mohan ‘Al’ Chakrabarty 1938–2020

Published in Nature Biotechnology